Team

David Levison is the Founder, Chief Executive Officer, and Director of CardioDx. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer of XDx, Inc., a molecular diagnostic company focused on the immune system. Previously, he was the Founder, President and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark) in December 2001. Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. David also served as Chief Financial Officer of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David received his M.B.A. from Stanford University and his B.S. from Williams College.

Steven Rosenberg joined CardioDx in 2006 and is responsible for the scientific staff and for research and development programs in the areas of genomics, genetics, and informatics. In addition, Steven is currently on the Board of Directors of KMT Hepatech. Prior to joining CardioDx, Steven served for three years as the Chief Scientific Officer of XDx, Inc., a molecular diagnostics company focused on diseases of the immune system. He led the group responsible for developing AlloMap, a molecular diagnostic for heart transplant patients, the first genomics-based test in transplant immunology. Prior to XDx, Steven spent a year as a consultant and visiting scholar at the University of California, Berkeley. From 1981 to 2001 he was at Chiron Corporation, where he was named one of only three Chiron Research Fellows in the company's history. He received his Ph.D. in biochemistry from the University of California, Berkeley, and is the author of more than 40 scientific publications, and an inventor of more than 20 U.S. patents.

Mark Monane joined CardioDx in 2011 as Chief Medical Officer. Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on analyses of emerging biotechnology companies in the cardiovascular and cancer disease areas. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health. Before joining Medco, he was an assistant professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness. Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. degree in health policy from Harvard University, and an M.D. from New York University.

Andrew Guggenhime joined CardioDx in 2011 as Chief Financial Officer. Andrew has more than 10 years of CFO experience, including more than nine years as CFO of a public company. Most recently, he served as CFO for Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company acquired in April 2011 by Gilead Sciences. Prior to Calistoga Pharmaceuticals, Andrew served as Senior Vice President and Chief Financial Officer for Facet Biotech Corporation, a publicly-held company acquired in April 2010 by Abbott Laboratories. He also served as CFO for PDL BioPharma, Inc., a publicly-held biopharmaceutical company, and Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds a B.A. from Middlebury College, and an M.M. from the J.L. Kellogg Graduate School of Management at Northwestern University.

Deborah Kilpatrick joined CardioDx in 2006 as Vice President, Market Development, with responsibility for building the marketing and reimbursement capabilities of the company. She currently oversees commercial functions that include provider marketing and sales, managed care marketing and sales, market access, and public relations. Prior to joining CardioDx she spent 9 years at the Vascular Intervention Division of Guidant Corporation where her roles included Research Fellow, Director of Research and Technology Development, and Director of New Ventures. Deborah serves on the Advisory Boards for the Georgia Institute of Technology and its College of Engineering. She is on the Board of Directors for the Dystonia Medical Research Foundation and is a Fellow of the American Institute of Medical and Biological Engineering. Deborah is a founder of the annual MedtechVision Conference in Silicon Valley and has received a Rising Star award from the Healthcare Businesswoman's Association. She holds multiple U.S. patents and a Ph.D. in mechanical engineering with a focus in cardiovascular bioengineering from the Georgia Institute of Technology.

Eric Sandberg is Senior Vice President, Sales, with responsibility for both provider and managed care field sales. He joined CardioDx in October of 2008 as Vice President, Sales, and has broad experience in the medical technology industry in a variety of sales, marketing, and business development leadership roles. Prior to joining CardioDx, he held Sales Director positions in the Vascular Intervention and Cardiac Rhythm Management divisions of Guidant Corporation and Boston Scientific. Eric's early career was spent with Eli Lilly and Company in various engineering roles. He received his B.S., magna cum laude, in mechanical engineering from Bradley University and his M.B.A. from Harvard Business School.

Susan Daniels joined CardioDx in 2004, and is responsible for the development of the company's genomic testing products. She has more than 17 years of experience in the genomics industry. Prior to CardioDx, Susan served as Vice President of Curation Sciences at Incyte, where she was responsible for managing the development of genomic-information products. In that role, she managed several multimillion-dollar drug discovery and target validation collaborations with pharmaceutical companies. Prior to joining Incyte, Susan was a Senior Scientist at Axys Pharmaceuticals (formerly Sequana Therapeutics), where she managed projects focused on mapping genes linked to complex inflammatory disorders. Her postdoctoral research was carried out at the Wellcome Trust Centre for Human Genetics at Oxford University. There she completed a genome-wide linkage analysis study that led to the identification of a number of genes associated with asthma. Susan received her Ph.D. in biochemistry from the University of Wales, Cardiff, in the United Kingdom.

Diane Johnson joined CardioDx in 2011 with responsibility for driving healthcare provider and patient access for the company’s product in the U.S. by working with payers. She currently leads a payer sales organization focused on securing favorable-coverage policies and managed care contracts for all CardioDx products. Diane has an extensive background in pharmaceuticals and biotechnology for coronary disease and cardiac arrhythmia through her roles at Knoll Pharmaceutical Company and Biovail Corporation. Before joining CardioDx, she developed and commercialized payer strategies for CV Therapeutics, and served as Senior Director of National Accounts in the managed care sales organization for Gilead Sciences. Diane began her career as a coronary nurse in Ohio, where she completed her nursing training at St. Elizabeth Health Center and Youngstown State University.

Gwen Carscadden joined CardioDx in 2012 as Vice President, Human Resources. She has more than 25 years of human resources experience, with various roles of increasing scope and responsibility. Most recently, she provided executive level human resources consulting services to several Bay Area biotechnology companies. Prior to that, she served as Vice President, Human Resources for Facet Biotech, which was acquired by Abbott Laboratories. Gwen previously served as Executive Director of Human Resources for PDL Biopharma. She began her career in the high-tech sector, working for Amdahl Corporation and Fujitsu Computer Systems. Gwen holds an M.A. in organizational communication from San Jose State University, and a B.A. in behavioral sciences also from San Jose State.